New insights into the pathobiology and treatment of chronic myelogenous leukemia.
Chronic myelogenous leukemia (CML) is one of the most frequently diagnosed forms of leukemia. Recent advances in the understanding of the molecular mechanisms involved in the pathogenesis of this disorder led to new diagnostic and therapeutic approaches. From a disease that used to be diagnosed purely on morphologic grounds, CML is now an entity that cannot be diagnosed in the absence of relevant cytogenetic or molecular data. Identification of the characteristic t(9;22) cytogenetic abnormality or of the BCR-ABL molecular abnormality is mandatory, as current treatment approaches rely on the use of agents active against this specific molecular target. This article presents the evolution in the understanding of the pathogenic mechanisms involved in CML, as well as the methods and the criteria currently in use in its diagnosis and treatment.
Cotta
Claudiu V
CV
Division of Pathology and Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.
Bueso-Ramos
Carlos E
CE
D003937:Diagnosis, Differential; D015972:Gene Expression Regulation, Neoplastic; D016313:Genes, abl / Q000235:genetics; D006801:Humans; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D011379:Prognosis; D014178:Translocation, Genetic